10X Genomics Inc is a biotechnology company focused on advancing the field of genomics through innovative technologies that enable researchers to explore biological systems at a single-cell level. The company's mission is to empower scientists to unlock the complexities of biology and disease by providing high-resolution genomic analysis tools. 10X Genomics Inc employs a strategy centered on continuous innovation and collaboration with the scientific community, offering a range of products that enhance genomic sequencing, gene expression analysis, and spatial biology. Their operations are driven by a commitment to improving human health through groundbreaking research and discoveries in genomics.

10X GENOMICS INC

10x Genomics, Inc. (NASDAQ: TXG) recently held its Q4 2024 earnings conference call on February 12, 2025, where CEO Serge Saxonov and executives discussed the company's performance for the fourth quarter and the full year ended December 31, 2024. Crucially, the company anticipates revenues for 2025 to fall between $610...

10x Genomics Reports Decline in Q4 Revenues and Projects Stagnant Growth Amid NIH Funding Cap Concerns

10x Genomics faces a challenging landscape as it reports a 10% decline in Q4 revenues and anticipates stagnant growth due to potential NIH funding caps. With over 60% of its customer base relying on this funding, can the company adapt and innovate to overcome these hurdles?